MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Afzelius, L.
Right arrow Articles by Masimirembwa, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Afzelius, L.
Right arrow Articles by Masimirembwa, C. M.

Vol. 59, Issue 4, 909-919, April 2001

Competitive CYP2C9 Inhibitors: Enzyme Inhibition Studies, Protein Homology Modeling, and Three-Dimensional Quantitative Structure-Activity Relationship Analysis

Lovisa Afzelius, Ismael Zamora, Marianne Ridderström, Tommy B. Andersson, Anders Karlén, and Collen M. Masimirembwa

Department of Drug Metabolism and Pharmacokinetics & Bioanalytical Chemistry, AstraZeneca R&D, Mölndal, Sweden (L.A., I.Z., M.R., T.B.A., C.M.M.); and Department of Organic Pharmaceutical Chemistry, Biomedical Center, Uppsala University, Uppsala, Sweden (L.A., A.K.)

This study describes the generation of a three-dimensional quantitative structure activity relationship (3D-QSAR) model for 29 structurally diverse, competitive CYP2C9 inhibitors defined experimentally from an initial data set of 73 compounds. In parallel, a homology model for CYP2C9 using the rabbit CYP2C5 coordinates was built. For molecules with a known interaction mode with CYP2C9, this homology model, in combination with the docking program GOLD, was used to select conformers to use in the 3D-QSAR analysis. The remaining molecules were docked, and the GRID interaction energies for all conformers proposed by GOLD were calculated. This was followed by a principal component analysis (PCA) of the GRID energies for all conformers of all compounds. Based on the similarity in the PCA plot to the inhibitors with a known interaction mode, the conformer to be used in the 3D-QSAR analysis was selected. The compounds were randomly divided into two groups, the training data set (n = 21) to build the model and the external validation set (n = 8). The PLS (partial least-squares) analysis of the interaction energies against the Ki values generated a model with r2 = 0.947 and a cross-validation of q2 = 0.730. The model was able to predict the entire external data set within 0.5 log units of the experimental Ki values. The amino acids in the active site showed complementary features to the grid interaction energies in the 3D-QSAR model and were also in agreement with mutagenesis studies.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A.-C. Egnell, J. B. Houston, and C. S. Boyer
Predictive Models of CYP3A4 Heteroactivation: In Vitro-in Vivo Scaling and Pharmacophore Modeling
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 926 - 937.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Afzelius, F. Raubacher, A. Karlen, F. S. Jorgensen, T. B. Andersson, C. M. Masimirembwa, and I. Zamora
STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
Drug Metab. Dispos., November 1, 2004; 32(11): 1218 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A.-C. Egnell, C. Eriksson, N. Albertson, B. Houston, and S. Boyer
Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 878 - 887.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kumar, E. E. Scott, H. Liu, and J. R. Halpert
A Rational Approach to Re-engineer Cytochrome P450 2B1 Regioselectivity Based on the Crystal Structure of Cytochrome P450 2C5
J. Biol. Chem., May 2, 2003; 278(19): 17178 - 17184.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Spatzenegger, H. Liu, Q. Wang, A. Debarber, D. R. Koop, and J. R. Halpert
Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular Modeling
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 477 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. M. Hutzler, D. Kolwankar, M. A. Hummel, and T. S. Tracy
Activation of CYP2C9-Mediated Metabolism by a Series of Dapsone Analogs: Kinetics and Structural Requirements
Drug Metab. Dispos., November 1, 2002; 30(11): 1194 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Wang and J. R. Halpert
Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modeling
Drug Metab. Dispos., January 1, 2002; 30(1): 86 - 95.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Y. H. Leung, H. C. H. Chow, Y. L. Kwong, A. K. W. Lie, A. T. K. Fung, W. H. Chow, A. S. B. Yip, and R. Liang
Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients
Blood, October 15, 2001; 98(8): 2584 - 2587.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics